参考文献/References:
[1] 毛丽伟,管静芝,廖国清.S-1联合DDP腹腔循环热灌注治疗老年胃癌合并腹水临床疗效观察[J].现代肿瘤医学,2014,22(12):2916-2918.
[2] 简 朔.替吉奥联合顺铂腹腔恒温循环热灌注治疗对胃癌合并腹水患者恶性分子表达的影响及毒副反应评估[J].海南医学院学报,2016,22(15):1730-1732.
[3] 〖JP2〗韩熙渊.替吉奥联合顺铂腹腔热灌注化疗治疗胃癌合并腹水17例临床观察[J].中国医药指南,2015,13(3):202-202.〖JP〗
[4] 陈 宓.阿帕替尼联合热疗治疗晚期胃癌恶性腹水的临床研究[J].医药前沿,2016,6(36):123-125.
[5] 毛丽伟,王 阳,廖国清.腹腔热灌注化疗对晚期胃癌患者外周血和腹水调节性T细胞的影响及意义[J].检验医学与临床,2016,13(17):2429-2431.
[6] 齐 瑾,郑玉军,王明吉.洛铂腹腔灌注联合替吉奥治疗晚期胃癌合并腹水的临床观察[J].中国当代医药,2014,21(14):92-94.
[7] 李玉珠,李亚平.腹腔灌注顺铂联合口服替吉奥治疗胃癌合并恶性腹水的疗效及安全性[J].中国现代药物应用,2016,10(21):135-136.
[8] 邓正兴.腹腔灌注顺铂联合口服替吉奥治疗胃癌合并恶性腹水的效果及安全性分析[J].中国当代医药,2015,22(26):49-51.
[9] 柯于锋.替吉奥联合腹腔内化疗治疗胃癌合并腹腔积液的疗效观察[J].当代医学,2014,20(29):1238-1240.
[10] 王海存,曹 旸,王兰荣.替吉奥联合顺铂腹腔恒温循环热灌注化疗对胃癌合并腹水患者恶性分子及免疫功能的影响[J].中国老年学,2016,36(23):5894-5896.
[11] 尚红娟,黄龙璋,邓泽锋.替吉奥联合腹腔化疗方案治疗胃癌腹水的临床效果观察[J].中国当代医药,2014,21(25):99-101.
[12] Do KT, Kastenmüller G, Mook-Kanamori DO.Network-based approach for analyzing intra- and interfluid metabolite associations in human blood, urine, and saliva[J].Journal of Proteome Research,2014,14(2):1183.
[13] Inman BA, Etienne W, Rubin R.The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment[J].Int J Hyperthermia,2013,29(3):206-210.
[14] Hasan MM, Nayem KA, Hossain MB.Production of Tissue Engineering Scaffolds from Poly Caprolactone (PCL) and Its Microscopic Analysis[J].International Journal of Textile Science,2014,3(3):39-43.
[15] Abiose SH, SH Ikujenlola SH, Aboderin FI.Nutritional quality assessment of complementary foods produced from fermented and malted Quality Protein Maize fortified with soy bean flour[J].Polish Journal of Food & Nutrition Sciences,2015,65(1):49-56.
[16] Hillyer M, Menon K, Singh R.The effects of dehydration on skill-based performance[J].International Journal of Sports Science,2015,5(3):99-107.
[17] Ammerlaan W,Trezzi JP,Mathay C.Method validation for preparing urine samples for downstream proteomic and metabolomic applications[J].Biopreservation & Biobanking,2014,12(5):351-357.
[18] 宾业鸿,郑海平,蓝 东.SOX联合多西他赛腹腔灌注与DOS方案一线治疗晚期胃癌伴癌性腹水的对比研究[J].中华肿瘤防治杂志,2016,23(16):1085-1089.
[19] 类成海,颜 慧.替吉奥联合奥沙利铂治疗老年晚期胃癌患者的临床疗效及安全性观察[J].中国实用医药,2017,12(5):137-138.
[20] 陈 敏,李亚妮.热疗联合替吉奥单药治疗老年晚期胃癌的临床观察[J].中南医学科学杂志,2016,44(6):610-612.
相似文献/References:
[1]侯洁心 ,郭萍△.免疫组化标志物Her2和肿瘤标志物在胃癌诊断中的价值分析*[J].陕西医学杂志,2019,(1):121.
HOU Jiexin,GUO Ping..The value of immunohistochemical marker Her2 andtumor markers in the diagnosis of gastric cancer[J].,2019,(4):121.
[2]刘国庆,闫 龙△,高 任.1.5T磁共振扩散加权成像在胃癌淋巴结转移诊断中的应用价值*[J].陕西医学杂志,2019,(4):456.
LIU Guoqing,YAN Long,GAO Ren..1.5T magnetic resonance diffusion weighted imaging in the diagnosis of lymph node metastasis of gastric cancer[J].,2019,(4):456.
[3]胡乃军,王海龙.胃腺癌组织中MMP11、MMP12和VEGFD的表达及临床意义[J].陕西医学杂志,2019,(5):554.
[4]米志宽,赵菊梅.抑癌基因甲基化与胃癌关系研究进展*[J].陕西医学杂志,2019,(5):679.
MI Zhikuan,ZHAO Jumei..Research progress of relationships between tumor suppressor gene methylation and gastric cancer[J].,2019,(4):679.
[5]石颖鹏,王敏娟,李程亮.肠化生相关分子与胃癌的发生和进展研究概况[J].陕西医学杂志,2019,(7):958.
SHI Yingpeng,WANG Minjuan,LI Chengliang,et al.Intestinal metaplasia-related molecules and the occurrence and progress of gastric cancer[J].,2019,(4):958.
[6]郭小艳,于桂萍.抗幽门螺杆菌疗法联合新辅助化疗对胃癌术后疗效及患者血清VEGF、bFGF的影响[J].陕西医学杂志,2019,(8):1010.
GUO Xiaoyan,YU Guiping..Effect of anti-Helicobacter pylori therapy combined with neoadjuvant chemotherapy on serum VEGF and bFGF in postoperative patients with gastric cancer[J].,2019,(4):1010.
[7]柯东平,毛俊倩,郭甲民,等.SCNN1B与胃癌细胞上皮间质转化相关性实验研究*[J].陕西医学杂志,2019,(9):1115.
KE Dongping,MAO Junqian,GUO Jiamin,et al.Research on the correlation between SCNN1B and〖JZ〗 epithelialmesenchymal transformation in gastric cancer cells[J].,2019,(4):1115.
[8]王小林,马任远,张 哲.腹腔镜手术治疗老年进展期胃癌50例临床疗效分析[J].陕西医学杂志,2019,(10):1360.
[9]刘维帅,郭晓宁,杨 洋,等.胃癌病理类型及临床预后与血清miR-133a和DKK-1相关性分析[J].陕西医学杂志,2020,49(6):751.[doi:DOI:10.3969/j.issn.10007377.2020.06.028]
LIU Weishuai,GUO Xiaoning,YANG Yang,et al.Correlation of pathological types and clinical prognosis of gastric cancer with serum miR-133a and DKK-1[J].,2020,49(4):751.[doi:DOI:10.3969/j.issn.10007377.2020.06.028]
[10]张 铭,张新望,艾 静,等.胃癌患者血浆微小RNA-100表达水平及其临床意义*[J].陕西医学杂志,2020,49(7):893.[doi:DOI:10.3969/j.issn.10007377.2020.07.034]
ZHANG Ming,ZHANG Xinwang,AI Jing,et al.Study on expression level of microRNA-100 in plasma of patients with gastric cancer[J].,2020,49(4):893.[doi:DOI:10.3969/j.issn.10007377.2020.07.034]